VitD3 Supplementation in Patients With Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate post-transplant immune reconstitution and
lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple
myeloma in two treatment arms. One arm will receive lenalidomide and an intensified regimen
of maintenance VitD, and the other arm will receive lenalidomide and a therapeutic regimen of
VitD. This clinical trial will also evaluate the overall response rate and survival for both
treatment arms.
Phase:
Early Phase 1
Details
Lead Sponsor:
Amany Keruakous, MD, MS.
Treatments:
Cholecalciferol Ergocalciferols Lenalidomide Vitamin D Vitamins